The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from CNW Group

Amorfix to present cancer therapeutic program at AACR 2013

Thursday, January 24, 2013

Amorfix to present cancer therapeutic program at AACR 201307:00 EST Thursday, January 24, 2013TSX: AMFTORONTO, Jan. 24, 2013 /CNW/ - Amorfix Life Sciences Ltd. announced today that the company has been selected to present an oral platform entitled "AMF-1c-120: an antibody specific for misfolded prion protein expressed on ovarian cancer cells", at the annual meeting of the American Association for Cancer Research (AACR) in Washington, DC on April 9, 2013.The Company will present the results of studies demonstrating the selective binding of its proprietary antibody, AMF-1c-120, to ovarian cancer cells, but not normal ovarian cells, as well as the killing of ovarian cancer cells with an antibody-toxin conjugate. These results validate the Company's ProMIS™ discovery technology as a valuable scientific platform enabling the development of novel, targeted therapeutic antibodies for the treatment of cancer and other diseases.Dr. Neil Cashman, Amorfix's Chief Scientific Officer said, "It is an honour to be one of the few participants selected for an oral presentation at this premier cancer research conference. We look forward to sharing our exciting results with the scientific community working to battle this common and terrible disease".The Company is developing AMF-1c-120 as a new therapeutic for the treatment of ovarian cancer and is in preclinical animal models of disease at present.  The Company is also developing additional antibodies for the treatment of other types of cancers with their unique and proprietary ProMIS™ platform for identifying cancer specific targets that spare normal cells.About the ProMIS Discovery Technology and the Company's Prion Protein (PrP) TargetAmorfix's proprietary drug discovery technology, ProMIS™, is a computer based algorithm that predicts Disease Specific Epitopes (DSEs), those regions of proteins most likely to misfold in diseases. Misfolded proteins are found in numerous diseased cells, including various cancers and neurodegenerative diseases. The Company uses this technology to identify DSEs which are only expressed on tumor cells and not on normal cells as a way of developing antibodies that only bind to and kill tumor cells without affecting normal cells. Using this technology, Amorfix has the potential to create antibody therapeutics that are more efficacious and have a much better safety profile, with fewer side effects than current cancer therapeutics.About Ovarian CancerOvarian cancer is the fifth most common cancer among women, and it causes more deaths than any other type of female reproductive cancer. Most deaths from ovarian cancer occur in women age 55 and older. Ovarian cancer is often not diagnosed until late-stage disease when the cancer has spread to other organs in the body, which contributes to the short survival time following diagnosis. Ovarian cancer is typically treated with surgery and chemotherapy. Chemotherapy is not very effective as a treatment and is associated with a number of potential dose-limiting side effects due to its non-specific killing of both tumour and normal cells. About AmorfixAmorfix Life Sciences Ltd. (TSX:AMF) is an early-stage product development company developing therapeutic antibodies and diagnostics targeting misfolded protein diseases. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this technology, Amorfix is developing novel antibody therapeutics and companion diagnostics for cancer and amyotrophic lateral sclerosis (ALS). In addition, Amorfix has developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample: Epitope Protection™ and AMFIA™, an ultra-sensitive dual-bead immunoassay. Use of these technologies has generated a human cerebrospinal fluid (CSF) screening test for Alzheimer's disease (AD) and mild cognitive impairment (MCI), and an ultrasensitive method for detecting the hallmark of AD, aggregated beta-Amyloid, in brain tissue, CSF and blood from animal models of AD. For more information about Amorfix, visit www.amorfix.comThe TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law.ProMIS™, Epitope Protection™ and AMFIA™ are trademarks of Amorfix Life Sciences Ltd.SOURCE: Amorfix Life Sciences Ltd.For further information: Dr. Robert Gundel President and Chief Executive Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6957 Fax: (416) 847-6899 bob.gundel@amorfix.com Janet Clennett Chief Financial Officer Amorfix Life Sciences Ltd. Tel: (416) 847-6926 Fax: (416) 847-6899 janet.clennett@amorfix.com